格拉司琼预防^(131)I“清甲”治疗术后DTC患者呕吐的临床研究  

Preventive efficacy of Granisetron for nausea and vomiting after ^(131)I therapy in patients with differentiated thyroid carcinoma

作　　者：赵志刚[1] 彭亮[1] 李亚军[1] 李长越[1] 吴晓杰[1] 廉英[1] 孟丹[1] 司丽霞[1] 赵岩灵 谢路林[1] 聂江[1] 王晶[1] 张晓平[1] 庄岚[1] 

机构地区：[1]解放军第210医院核医学科,辽宁大连116015

出　　处：《临床军医杂志》2014年第9期904-905,911,共3页Clinical Journal of Medical Officers

摘　　要：目的探讨格拉司琼预防分化型甲状腺癌(DTC)患者^(131)I"清甲"术后呕吐的疗效。方法将行甲状腺全/近全切除术后经病理确诊为甲状腺乳头状癌患者285例,随机分为对照组142例、治疗组143例,对照组采用口服多潘立酮,治疗组采用口含盐酸格拉司琼口腔崩解片以预防呕吐发生。结果治疗组患者呕吐发生率(2.1%),低于对照组患者(9.2%),两组比较,差异有统计学意义(x^2=5.781,P<0.05)。结论口含盐酸格拉司琼口腔崩解片有较好的预防DTC患者^(131)I"清甲"治疗术后呕吐的作用。Objective To investigate the efficacy of Granisetron for nausea and vomiting after 131 I therapy in patients with differ- entiated thyroid carcinoma. Methods Totally 285 patients with pathologically diagnosed papillary thyroid carcinoma after subtotal thyroidectomy or whole cutting operation were randomized into trial group （ n = 143 ） and control group （ n = 142 ）. The control group was given oral Domperidone to prevent vomiting and trial group was given orally disintegrating tablets of Granisetron hydrochlo- ride. Results The incidence of vomiting in the trial group was 2.1% , significantly lower than that （9.2%） in the control group （ χ^2 = 5.781, P 〈 0.05 ）. Conclusion Granisetron hydrochloride orally disintegrating tablets can prevent vomiting effectively after 131I therapy in patients with differentiated thyroid carcinoma.

关 键 词：131I 分化型甲状腺癌 不良反应 

分 类 号：R817.8[医药卫生—影像医学与核医学]